Whitebox Advisors’s Ibere Pharmaceuticals IBER Stock Holding History

Whitebox Advisors’s Portfolio IBER Stock Details IBER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-75,246	Closed	-$759K	–	736
2022 Q4	$759K	Hold	75,246	–	–	0.02%	335
2022 Q3	$746K	Hold	75,246	–	–	0.02%	417
2022 Q2	$738K	Hold	75,246	–	–	0.02%	410
2022 Q1	$738K	Sell	75,246 -6,000	-7%	-$58.5K	0.01%	435
2021 Q4	$790K	Buy	81,246 +6,246	+8%	+$60.7K	0.02%	390
2021 Q3	$727K	Hold	75,000	–	–	0.02%	358
2021 Q2	$725K	Buy	+75,000	New	+$730K	0.01%	310

Whitebox Advisors's IBER Position: Q1 2023 in Review

Whitebox Advisors sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 75,246 shares — an estimated $759K sold.

Whitebox Advisors first reported a position in IBER in Q2 2021 and held it in 7 quarters. The position peaked at $790K in Q4 2021. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

Whitebox Advisors reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Whitebox Advisors sold 75,246 Ibere Pharmaceuticals shares in Q1 2023, an estimated $759K.
Whitebox Advisors first reported a position in Ibere Pharmaceuticals in Q2 2021 and held it in 7 quarters.
Whitebox Advisors's Ibere Pharmaceuticals position peaked at $790K in Q4 2021.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on Whitebox Advisors's 13F filing for Q1 2023, filed 15 May 2023.